SaaS
United States
verified
NEW
Modern at-home allergy immunotherapy that replaces years of in-office shots
Asking price
$2.9M
Revenue
$2,230,471
Profit
-91869
Growth
88%
Churn
1-3%
Customers
1,000-5,000
Description
This is a national telehealth platform focused on physician-guided, at-home allergy immunotherapy via a subscription model, helping patients access long-term, disease-modifying treatment without frequent in-office visits, while operating a fully compliant infrastructure licensed across all 50 states with integrated clinical, pharmacy, and technology workflows that support durable recurring revenue through multi-year treatment durations, strong retention, and efficient customer acquisition, alongside a rapidly scaling B2B channel that enables medical practices to offer allergy treatment without added operational complexity in a large, underserved chronic-care market.
Key Highlights
✅ Modern at-home allergy immunotherapy delivered through a subscription model with physician oversight
✅ Fully compliant infrastructure licensed across all 50 states with integrated clinical, pharmacy, and technology workflows
✅ Durable recurring revenue supported by multi-year treatment durations, strong retention, and efficient customer acquisition
✅ Rapidly scaling B2B channel that enables medical practices to offer allergy treatment without added operational complexity
✅ Scalable, capital-efficient platform serving a large, underpenetrated segment of chronic care with long-term growth potential
Competitors
Hims
Ro
Friday
Mochi
Highlights
Intellectual property
Customers
Mobile application
Website
Domain
Trademarks
Copyright
Codebase
Social media accounts
Patents
Trade names
Marketing materials
Brand